Acasti Pharma Inc. (ACST)

NASDAQ: ACST · IEX Real-Time Price · USD
0.351
-0.005 (-1.38%)
At close: Dec 9, 2022 4:00 PM
0.378
+0.027 (7.82%)
After-hours: Dec 9, 2022 6:08 PM EST
-1.38%
Market Cap 16.32M
Revenue (ttm) n/a
Net Income (ttm) -17.14M
Shares Out 44.55M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 161,702
Open 0.36
Previous Close 0.356
Day's Range 0.35 - 0.364
52-Week Range 0.35 - 1.79
Beta 1.26
Analysts Buy
Price Target n/a
Earnings Date Nov 14, 2022

About ACST

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada. [Read more]

Industry Pharmaceuticals
CEO Janelle D'Alvise
Employees 32
Stock Exchange NASDAQ
Ticker Symbol ACST
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Buy
Stock Forecasts

News

Acasti Pharma Reports Second Quarter 2023 Operational Results

Company to Host Conference Call Today at 1:00pm ET

3 weeks ago - GlobeNewsWire

Acasti Pharma to Present at Q4 Investor Summit

LAVAL, Québec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug...

1 month ago - GlobeNewsWire

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

Call to be held on Monday, November 14th at 1:00 PM Eastern Time Call to be held on Monday, November 14th at 1:00 PM Eastern Time

1 month ago - GlobeNewsWire

Acasti Announces Court Dismissal of Stockholder Litigation

LAVAL, Québec, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dru...

2 months ago - GlobeNewsWire

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dru...

2 months ago - GlobeNewsWire

Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and...

2 months ago - Newsfile Corp

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

LAVAL, Québec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and ...

2 months ago - GlobeNewsWire

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatme...

LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridgi...

2 months ago - GlobeNewsWire

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and ...

2 months ago - GlobeNewsWire

Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

Call to be held on Thursday, August 11th at 1:00 PM Eastern Time

4 months ago - GlobeNewsWire

Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - July 7, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and novel...

5 months ago - Newsfile Corp

Acasti Pharma Announces Annual Grants of Performance Stock Options

LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and t...

5 months ago - GlobeNewsWire

Acasti Pharma Reports Fiscal Year 2022 Operational Results

Company to Host Conference Call Today at 1:00pm ET

5 months ago - GlobeNewsWire

Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call

Call to be held on Tuesday, June 21st at 1:00 PM Eastern Time Call to be held on Tuesday, June 21st at 1:00 PM Eastern Time

5 months ago - GlobeNewsWire

Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

LAVAL, QC , May 23, 2022 /PRNewswire/ -- Acasti Pharma Inc. (Nasdaq: ACST and TSX-V: ACST) ("Acasti"; the "Company"), a late-stage specialty pharmaceutical company with drug delivery technologies and dr...

6 months ago - PRNewsWire

Acasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine

Acasti Pharma Inc's (NASDAQ: ACST) pharmacokinetic (PK) bridging study with IV GTX-104, its lead drug candidate for Subarachnoid Hemorrhage (SAH), met all its planned study endpoints.  The study's prima...

6 months ago - Benzinga

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All End...

Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for GTX-104

6 months ago - GlobeNewsWire

Update: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 18th

LAVAL, QC / ACCESSWIRE / May 16, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq:ACST) and (TSX-V:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to pre...

6 months ago - Accesswire

Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th

LAVAL, QC / ACCESSWIRE / May 12, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST)(TSXV:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to present a...

6 months ago - Accesswire

Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th

LAVAL, Québec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Prashant Kohli, Vice President of Commercial Operati...

7 months ago - GlobeNewsWire

Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announces that it has appointed Michael L. Derby to its Board of Dir...

8 months ago - GlobeNewsWire

Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan

LAVAL, Québec, March 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), announces the following patent notifications and awards relating to the C...

8 months ago - GlobeNewsWire

Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th

LAVAL, Quebec, March 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D'Alvise, President and Chief Executive Officer ...

9 months ago - GlobeNewsWire

Acasti Pharma Celebrates Rare Disease Day

CEO Jan D'Alvise participates in educational interviews regarding rare diseases, including subarachnoid hemorrhage, ataxia-telangiectasia and postherpetic neuralgia CEO Jan D'Alvise participates in educ...

9 months ago - GlobeNewsWire

New Strong Sell Stocks for February 23rd

ARR, ACST, and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on February 23, 2022

Other symbols: ARRATUS
9 months ago - Zacks Investment Research